EN DE
Watch GENNEX LABORATORIES LTD. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

GENNEX LABORATORIES LTD. (GENNEX) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of GENNEX LABORATORIES LTD. stock ₹14.68, price ₹9.10, upside +61.3%, quality 28 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE509C01026

GL GENNEX LABORATORIES LTD. logo Thin data Nov 14, 2026

GENNEX LABORATORIES LTD.

GENNEX · BSE

Cheap (38% below fair value), but weak company and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value ₹14.68 · Strongly undervalued 
Solidly profitable · 11.6% net margin (TTM) 
Low debt 
Ranks above peers (10/12) 
Revenue last quarter +17% vs. a year ago. 
Expensive Growth (revenue 5y +23.7 %/yr in INR) 
Moderate moat 47/100 · thin data
Quality 28/100 
Falling price (downtrend) 
Negative free cash flow 
Thin data 
Watch GENNEX LABORATORIES LTD. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹27.87 ₹4.99 Fair Value ₹14.68 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹4.99 – ₹27.87 · fair‑value band ₹11.01 – ₹18.35 · the ₹9.10 price screens below the ₹14.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow GENNEX LABORATORIES in your weekly email

Every Wednesday you see whether GENNEX LABORATORIES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Stock analysis

GENNEX LABORATORIES LTD. (GENNEX) currently trades at ₹9.10, while our model-based Fair Value estimate is ₹14.68, implying the stock looks roughly 38% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹27.20 per share, and 9 of the 14 models we run sit above the ₹9.10 price.

Bear case: the Asset-Based group reads lowest at ₹5.70, and 5 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹11.01 (bear) to ₹18.35 (bull), the price of ₹9.10 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

GENNEX LABORATORIES LTD. reported revenue of ₹1.7B in FY2025 versus ₹612M in FY2021, a compound +29.6%/yr. Reported net income was ₹210M in FY2025, compounding +52.1%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Key figures

Market cap ₹2.2B (≈ $23.5M) Micro · P/E ratio 11.8 · P/S ratio 1.24 · EPS (TTM) ₹0.7700 · Net margin 11.6% · Return on equity 9.8% · Return on assets (EBIT) 5.5% (5-year average) · Operating margin 9.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 39% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −21% fair-value upside, at 61%, GENNEX screens cheaper than that median.

Fair Value models

Bear ₹11.01 Fair Value ₹14.68 Bull ₹18.35
Price ₹9.10 · Upside +61.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (₹0.6772 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV ₹3.44 ₹4.07 ₹4.58 74
ROIC Compounder ₹3.44 ₹4.07 ₹4.58 72
Residual Income ₹7.11 ₹7.51 ₹8.38 71
All 14 models by family
Earnings-Based
Graham-Dodd ₹5.87 ₹40.95 ₹57.47 63
Lynch FV ₹14.36 ₹20.51 ₹26.66 61
PEG = 1.0 ₹14.36 ₹20.51 ₹26.66 57
EPV ₹3.44 ₹4.07 ₹4.58 74
Multiples
P/E Multiple ₹14.25 ₹19.00 ₹23.75 63
P/S Multiple ₹11.01 ₹14.68 ₹18.35 58
P/B Multiple ₹12.19 ₹16.26 ₹20.32 55
EV/EBIT ₹7.12 ₹10.58 ₹14.05 65
EV/EBITDA ₹6.43 ₹9.67 ₹12.90 66
EV/Revenue ₹4.15 ₹7.33 ₹10.50 52
Asset-Based
NCAV (Graham) ₹3.76 ₹5.70 ₹7.13 54
Economic Profit
Residual Income ₹7.11 ₹7.51 ₹8.38 71
ROIC Compounder ₹3.44 ₹4.07 ₹4.58 72
Growth Earnings
Growth-Adj P/E ₹19.04 ₹27.20 ₹35.37 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 39
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 61
Debt, balance sheet and risk of trouble
Investment 24
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 6
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+25.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.7%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.9% vs 15.5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 12%
Pace: the 5-year rate starts in 2020 (pandemic)

Watch GENNEX, get fair value alerts →

Compare GENNEX LABORATORIES LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)Health Care · 2780 stocks

Beats the sector median on 10/12 measures
Overall it ranks above its sector peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside +61.3% · Top 25%
Profitability
Return on equity (12 months) 9.8% · Above median
Return on assets 6.0% · Above median
Net margin (12 months) 11.6% · Above median
Operating margin (12 months) 9.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 16.6% · Above median
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Health Care median · lower = cheaper

P/E (12 months) 11.8× · Cheapest 25%
P/B 0.99× · Cheapest 25%
P/S (12 months) 1.24× · Cheapest 25%
EV/EBITDA 12.1× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 14
FUTURE (revenue growth)83 · sector 37
PAST (return on equity)39 · sector 8
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
UnitedHealth Group UNH $389.68 $532.82 +37% vs GENNEX
Novartis AG NOVN CHF 133.28 CHF 123.08 −8% vs GENNEX
Merck & Co MRK $143.37 $129.26 −10% vs GENNEX
AbbVie Inc ABBV $292.82 $259.62 −11% vs GENNEX
Roche Holding RO CHF 411.00 CHF 326.56 −21% vs GENNEX
CORALAB CORALAB ₹600.00 ₹468.58 −22% vs GENNEX
Johnson & Johnson, JNJ $278.70 $169.03 −39% vs GENNEX
BERLDRG BERLDRG ₹25.72 ₹15.48 −40% vs GENNEX
Eli Lilly and Company LLY $1,416 $749.92 −47% vs GENNEX
Anuh Pharma Limited 506260 ₹81.04 ₹30.19 −63% vs GENNEX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GENNEX LABORATORIES LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GENNEX LABORATORIES LTD. Fair Value". https://www.fairvalue-calculator.com/stock/GENNEX

Frequently asked questions

Is GENNEX LABORATORIES LTD. (GENNEX) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹14.68 versus a price of ₹9.10, about +61% upside (undervalued).
What is the fair value of GENNEX?
Our model-based fair value for GENNEX LABORATORIES LTD. is ₹14.68 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹9.10.
What is the quality score of GENNEX?
GENNEX LABORATORIES LTD. has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GENNEX LABORATORIES LTD. (GENNEX)?
Our model-based price target is the fair value of ₹14.68 (as of Nov 14, 2026) from 14 valuation models. Cautious scenario ₹11.01, optimistic scenario ₹18.35. It is a calculation from audited fundamentals, not an analyst target.
What is the GENNEX LABORATORIES LTD. stock forecast for 2026?
Our models put fair value at ₹14.68, about +61% upside versus a price of ₹9.10 (undervalued). Cautious scenario ₹11.01, optimistic scenario ₹18.35. The calculation is refreshed regularly with new filings.
What is the revenue of GENNEX LABORATORIES LTD. (GENNEX)?
GENNEX LABORATORIES LTD. reported trailing-twelve-month revenue of about ₹1.8B (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of GENNEX LABORATORIES LTD. (GENNEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GENNEX LABORATORIES LTD. it is ₹14.68 per share (as of Nov 14, 2026), against a price of ₹9.10. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is GENNEX LABORATORIES LTD. stock overvalued or undervalued in 2026?
As of Nov 14, 2026, GENNEX trades below its calculated fair value: price ₹9.10, fair value ₹14.68, a gap of about +61% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GENNEX?
No. The price is what the market pays today (₹9.10); the fair value is what the company's own numbers justify (₹14.68). For GENNEX LABORATORIES LTD. the two are ₹5.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is GENNEX LABORATORIES LTD. worth?
The market values GENNEX LABORATORIES LTD. at about ₹2.2B (market capitalisation, as of Nov 14, 2026). Per share that is ₹9.10; our models calculate a fair value of ₹14.68 per share.
What do the bullish and bearish scenarios say about GENNEX?
Our models span a range for GENNEX LABORATORIES LTD.: cautious scenario ₹11.01, base ₹14.68, optimistic ₹18.35 per share (as of Nov 14, 2026, price ₹9.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GENNEX?
GENNEX LABORATORIES LTD. trades at a price-to-earnings ratio of 11.8 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹14.68 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 22.3. Other multiples: P/B 1.0, P/S 1.2, EV/EBITDA 12.1.
How solid is the balance sheet of GENNEX LABORATORIES LTD. (GENNEX)?
Balance-sheet figures for GENNEX LABORATORIES LTD. (as of Nov 14, 2026): return on equity 9.8%, debt of 0.20 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is GENNEX from its 52-week high?
GENNEX LABORATORIES LTD. trades at ₹9.10, about 39% below its 52-week high of ₹15.01 and 28% above the low of ₹7.13 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹14.68 is for.
Which stocks are comparable to GENNEX LABORATORIES LTD.?
From the same area (Healthcare) we also value Anuh Pharma Limited, CORALAB, BERLDRG, Eli Lilly and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GENNEX LABORATORIES LTD. stock attractive at the current price?
The data as of Nov 14, 2026: price ₹9.10, calculated fair value ₹14.68 (+61%), Quality Score 28/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GENNEX calculated?
We run GENNEX LABORATORIES LTD. through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹14.68 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. GENNEX LABORATORIES LTD. currently trades 38% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GENNEX LABORATORIES LTD. (GENNEX)?
The closing price on Nov 17, 2026 was ₹9.10. Our model-based fair value is ₹14.68, about +61% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GENNEX LABORATORIES LTD. right now?
The large discount to fair value meets weak quality (28/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (₹11.01). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of GENNEX LABORATORIES LTD.

How large is the market capitalisation of GENNEX LABORATORIES LTD. (GENNEX)?
The market capitalisation of GENNEX LABORATORIES LTD. is ₹2.2B (≈ $23.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GENNEX LABORATORIES LTD. (GENNEX)?
The price-to-sales ratio of GENNEX LABORATORIES LTD. is 1.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GENNEX LABORATORIES LTD. (GENNEX)?
Earnings per share at GENNEX LABORATORIES LTD. are ₹0.7700 (price ÷ EPS = P/E 11.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GENNEX LABORATORIES LTD. (GENNEX)?
The net margin of GENNEX LABORATORIES LTD. is 11.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GENNEX LABORATORIES LTD. (GENNEX)?
The return on equity (ROE) of GENNEX LABORATORIES LTD. is 9.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GENNEX LABORATORIES LTD. (GENNEX)?
On an EBIT basis the return on assets of GENNEX LABORATORIES LTD. is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GENNEX LABORATORIES LTD. (GENNEX)?
The operating margin of GENNEX LABORATORIES LTD. is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GENNEX LABORATORIES LTD. (GENNEX)?
Revenue at GENNEX LABORATORIES LTD. is growing 16.6% versus a year earlier (3y avg +38.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GENNEX LABORATORIES LTD. (GENNEX)?
Earnings per share at GENNEX LABORATORIES LTD. are down 6.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does GENNEX LABORATORIES LTD. (GENNEX) generate?
The free cash flow of GENNEX LABORATORIES LTD. is −₹756M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GENNEX LABORATORIES LTD. (GENNEX) carry?
The net debt of GENNEX LABORATORIES LTD. is ₹793M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GENNEX LABORATORIES LTD. in the live analysis

One click puts GENNEX LABORATORIES LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.